October 2016

pharma courses

Addex Therapeutics announced that the company will conduct a phase IIa Proof of Concept Study of dipraglurant in focal cervical dystonia (CD). Addex expects to initiate the trial in the fourth quarter of 2016. The study was developed with support from the Dystonia Medical Research Foundation and in collaboration with investigators from the Dystonia Coalition, an international network of experts devoted to advancing research in dystonia. Buz Jinnah, Director of the Dystonia Coalition and Professor of Neurology at Emory University, will serve as the lead investigator.

[adsense:336x280:8701650588]

19 October 2016
Pfizer Announces The U.S. Availability Of Biosimilar INFLECTRA

INFLECTRA will be the first biosimilar monoclonal antibody (mAb) and only the second biosimilar to be available in the U.S. It is approved for the treatment of:
-adult patients and pediatric patients (ages six years and older) with moderate to severely active Crohn’s disease who have had an inadequate response to conventional therapy;
-adult patients with moderate to severely active ulcerative colitis who have had an inadequate response to conventional therapy; and
-moderate to severely active rheumatoid arthritis in combination with methotrexate; active ankylosing spondylitis; active psoriatic arthritis; and chronic severe plaque psoriasis.

Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration (FDA) approved TECENTRIQ® (atezolizumab) for the treatment of people with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities. This approval is based on results from the randomized Phase III OAK and Phase II POPLAR studies. The largest study, OAK, showed that TECENTRIQ helped people in the overall study population live a median of 13.8 months, 4.2 months longer than those treated with docetaxel chemotherapy (median overall survival [OS]: 13.8 vs. 9.6 months; HR = 0.74, 95% CI: 0.63, 0.87). The study enrolled people regardless of their PD-L1 status and included both squamous and non-squamous disease types.

Vedanta Biosciences, pioneering the development of a novel class of therapies for immune and infectious diseases based on rationally designed consortia of bacteria derived from the human microbiome, announced that the European Patent Office (EPO) has issued European Patent EP2575835. The patent broadly covers pharmaceutical compositions of Clostridium live bacterial strains and further expands Vedanta Biosciences’ patent portfolio after the issuances of three U.S. patents in the previous months and earlier issuances in Japan. The patents are exclusively licensed to Vedanta Biosciences under an agreement with the University of Tokyo and provide coverage through at least 2031.

18 October 2016
Vacancy for District Coordinator/ Pharmacist under NRHM | walk in

National Rural Health Mission is being implemented in the state constituting State Health Mission District Health Missions, State Health Society and District Health Societies. Kerala State Health and Family Welfare Society, named as “AROGYAKERALAM “ at the State level and District Health and Family Welfare Societies, named as “AROGYAKERALAM (indicate name of district)” ” in all the District Headquarters are registered societies under the Travancore Cochin Literary Scientific and Charitable Societies Registration Act 1955.

18 October 2016
Recruitment for experienced candidates in Pharmacovigilance at Quintiles IMS

Around the world healthcare stakeholders are working to improve real-world patient outcomes through treatment innovations, care provision and access to healthcare. For the information, technology and service solutions they need to drive new insights and approaches, they count on QuintilesIMS. With a global team of 50,000, we harness insights, commercial and scientific depth, and executional expertise to empower clients to achieve some of their most important goals: Improving clinical, scientific and commercial results.

18 October 2016
Opportunity in Lung Cancer project at Karunya University

Karunya University is a fully residential, Christian minority university located in Coimbatore, India. It was founded as a Christian minority institution by the late D. G. S. Dhinakaran, his son Paul Dhinakaran, Christian evangelists and the founders of Jesus Calls Ministries, India. This deemed university has been accredited by NAAC with a 'B' grade.

18 October 2016
Walk in for QA, QC and ADL at Cipla | Only experienced candidates

Cipla’s journey began in 1935 when our founder, Dr. K. A. Hamied, set up an enterprise with the vision to make India self-sufficient in healthcare. Over the past 77 years, we have emerged as one of the world’s most respected pharmaceutical names, not just in India but worldwide.
We have 34 state-of-the-art manufacturing facilities that make Active Pharmaceutical Ingredients (APIs) and formulations, which have been approved by major international Regulatory Agencies. We have over 2000 products in 65 therapeutic categories; with over 40 dosage forms, covering a wide spectrum of diseases ranging from communicable, non-communicable, common and emerging diseases to even rare diseases.

Cipla invites candidates for its API Virgonagar Plant in Bangalore.

Post: Quality Assurance/Quality Control Executive

18 October 2016
Applications Invited for the Post of Junior Research Fellow at INMAS

Institute of Nuclear Medicine and Allied Sciences (INMAS), Delhi under the aegis of Defence Research and Development Organisation (DRDO), is engaged in research and developmental work in radiation sciences. INMAS is looking for meritorious young researchers for pursuing research in the frontier areas at INMAS.